Business
Sernova Establishes Comprehensive North American Investor Relations and Communications Strategy
(via TheNewswire) US Program to Focus on Raising Company's Visibility Thro...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Establishes Comprehensive North American Investor Relations and Communications Strategy(via TheNewswire)\n \n \nUS Program to Focus on Raising Company's Visibility Through Engagement\n\n\n \n of Solebury Trout \n\n\n \nLONDON, ONTARIO / TheNewswire / November 6, 2018 - Sernova Corp (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company, today announced it has engaged Solebury Trout (\"Trout\"), a New York-based investor relations and strategic advisory consultant serving life science companies. \n\n\n \nSolebury Trout will develop and implement a comprehensive investor outreach program tailored to and in collaboration with Sernova that will include analyst and institutional and retail investor targeting/outreach, non-deal roadshows, corporate communications, and Key Opinion Leader (KOL) events in the chronic disease space.\n\n\n \n\"We have made significant progress in our diabetes program this year by advancing our US Phase I/II human clinical study of Sernova's Cell Pouch(TM) with insulin-producing cells and by announcing the HemAcure Consortium's achievements in developing a novel cell-based therapy for Hemophilia A. At this important juncture in the Company's history, the engagement of Solebury Trout advances our strategic initiative to expand awareness of Sernova in the investment community, particularly among US institutional investors,\" said Dr. Philip Toleikis, Chief Executive Officer of Sernova. \"The team at Trout, with its capital market and institutional experience, brings capabilities that will enable us to present Sernova's compelling story to a wide audience of investors, both in the U.S. and internationally.\" \n\n \n \n\"Sernova has the potential to transform the diabetes, hemophilia and other chronic diseases treatment landscape with their disruptive regenerative medicine technologies and Solebury Trout will provide Sernova with its biotechnology and life sciences industry experience.\" Stated Danny Matthews, Senior Associate at Solebury Trout.\n\n\n \nUnder the terms of the engagements, Solebury Trout has been retained for an extendable 12-month period for a monthly remuneration of US$16,500 plus direct expenses. Solebury Trout does not currently have any interest, either directly or indirectly, in the company. The agreement is subject to approval by the TSX Venture Exch...